A Metabolic-Related Gene Signature for Predicting Biochemical Recurrence After Radical Prostatectomy: An Integrative Analysis and Targeted Therapeutic Validation
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27114797 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Wankun Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Zhejiang University, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Metabolic Reprogramming, Neoplasm Recurrence, Local, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Fund of the National Health and Wellness Commission - Major Science and Technology Plan Project for Health and Wellness in Zhejiang Province.
Abstract (Originalsprache)
Biochemical recurrence (BCR) after radical prostatectomy (RP) remains a major clinical challenge. Although metabolic reprogramming drives prostate cancer (PCa) progression, its predictive value for BCR and its interplay with the tumor immune microenvironment (TIME) remain incompletely understood. By integrating weighted gene co-expression network analysis (WGCNA) with machine learning, we identified four metabolic-related hub genes (GDPD1, PLA2G7, PTGDS, and SRD5A2) and developed an XGBoost-Cox model that accurately stratified BCR risk (training 5-year AUC: 0.858; validation 5-year AUC: 0.745). SHAP analysis enhanced the model’s interpretability, while immunohistochemistry (IHC) validated differential protein expression of these targets across 32 clinical specimens. Furthermore, immune profiling demonstrated that these genes are closely linked to M2 macrophage-mediated immunosuppression and altered T-cell infiltration. To translate these biomarkers into therapeutic targets, we employed in silico screening, molecular docking, and molecular dynamics simulations, identifying (-)-epigallocatechin gallate (EGCG) as a promising multi-target candidate. Subsequent in vitro assays confirmed that EGCG binds stably to GDPD1, PTGDS, and SRD5A2, effectively suppressing malignant PCa phenotypes and prostate-specific antigen (PSA) secretion. In summary, we established a robust and interpretable model for predicting BCR after RP, and our in vitro validation suggests that EGCG holds promise as a therapeutic agent to delay PCa progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Zhejiang University, Hangzhou 310058, China.
- Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
ORCID-Profile: Wankun Wang, Xiujuan Hong, Zhibing Wu
Förderung
- Scientific Research Fund of the National Health and Wellness Commission - Major Science and Technology Plan Project for Health and Wellness in Zhejiang Province
Zitieren
APA
Wang, W., Hong, X., Wang, X., Jiao, G., Cai, H., Zhao, J., Wu, Z., & Chen, J. (2026). A Metabolic-Related Gene Signature for Predicting Biochemical Recurrence After Radical Prostatectomy: An Integrative Analysis and Targeted Therapeutic Validation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27114797
Vancouver
Wang W, Hong X, Wang X, Jiao G, Cai H, Zhao J, et al. A Metabolic-Related Gene Signature for Predicting Biochemical Recurrence After Radical Prostatectomy: An Integrative Analysis and Targeted Therapeutic Validation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27114797
BibTeX
@article{Wang2026,
author = {Wang, Wankun and Hong, Xiujuan and Wang, Xiaoqi and Jiao, Ganpei and Cai, Hongjie and Zhao, Junxiang and Wu, Zhibing and Chen, Jun},
title = {A Metabolic-Related Gene Signature for Predicting Biochemical Recurrence After Radical Prostatectomy: An Integrative Analysis and Targeted Therapeutic Validation},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27114797}
}
EUVIMED